Healthcare provider profile · identity verified

Kassi Michelle Marshall, MD

Internal Medicine · LEXINGTON, KY · NPI 1952413643

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	211	90
Pantoprazole Sodium	Pantoprazole Sodium	203	82
Lisinopril	Lisinopril	189	72
Gabapentin	Gabapentin	166	68
Levothyroxine Sodium	Levothyroxine Sodium	160	75
Albuterol Sulfate Hfa	Albuterol Sulfate	137	49
Rosuvastatin Calcium	Rosuvastatin Calcium	113	31
Eliquis	Apixaban	109	26
Metoprolol Tartrate	Metoprolol Tartrate	93	36
Potassium Chloride	Potassium Chloride	91	43
Fluticasone Propionate	Fluticasone Propionate	89	41
Amlodipine Besylate	Amlodipine Besylate	88	38
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	86	45
Tamsulosin Hcl	Tamsulosin Hcl	82	39
Montelukast Sodium	Montelukast Sodium	78	34
Metoprolol Succinate	Metoprolol Succinate	73	32
Ezetimibe	Ezetimibe	72	23
Metformin Hcl	Metformin Hcl	68	36
Furosemide	Furosemide	66	31
Omeprazole	Omeprazole	65	29
Trazodone Hcl	Trazodone Hcl	62	29
Hydrochlorothiazide	Hydrochlorothiazide	50	28
Carvedilol	Carvedilol	49	28
Clopidogrel	Clopidogrel Bisulfate	46	17
Oxycodone Hcl	Oxycodone Hcl	46	26
Finasteride	Finasteride	45	18
Alendronate Sodium	Alendronate Sodium	44	17
Duloxetine Hcl	Duloxetine Hcl	43	21
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	42	27
Diclofenac Sodium	Diclofenac Sodium	41	13
Famotidine	Famotidine	41	21
Losartan Potassium	Losartan Potassium	41	24
Venlafaxine Hcl Er	Venlafaxine Hcl	40	14
Meloxicam	Meloxicam	39	11
Escitalopram Oxalate	Escitalopram Oxalate	38	13
Farxiga	Dapagliflozin Propanediol	37	14
Isosorbide Mononitrate Er	Isosorbide Mononitrate	37	16
Prednisone	Prednisone	37	29
Clonazepam	Clonazepam	36	13
Nitroglycerin	Nitroglycerin	34	15
Lorazepam	Lorazepam	32	25
Memantine Hcl	Memantine Hcl	32	suppressed
Ropinirole Hcl	Ropinirole Hcl	32	14
Alprazolam	Alprazolam	31	suppressed
Buspirone Hcl	Buspirone Hcl	31	14
Jardiance	Empagliflozin	31	suppressed
Xifaxan	Rifaximin	30	suppressed
Baclofen	Baclofen	29	suppressed
Simvastatin	Simvastatin	28	15
Tizanidine Hcl	Tizanidine Hcl	28	13
Quetiapine Fumarate	Quetiapine Fumarate	27	14
Spironolactone	Spironolactone	27	11
Combivent Respimat	Ipratropium/Albuterol Sulfate	26	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	11
Pravastatin Sodium	Pravastatin Sodium	26	16
Esomeprazole Magnesium	Esomeprazole Magnesium	25	12
Mirtazapine	Mirtazapine	25	suppressed
Sertraline Hcl	Sertraline Hcl	25	12
Sucralfate	Sucralfate	25	13
Bupropion Xl	Bupropion Hcl	24	suppressed
Lactulose	Lactulose	24	16
Levetiracetam	Levetiracetam	24	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Bumetanide	Bumetanide	23	suppressed
Constulose	Lactulose	23	12
Donepezil Hcl	Donepezil Hcl	23	12
Mounjaro	Tirzepatide	23	suppressed
Nystatin	Nystatin	23	12
Pregabalin	Pregabalin	23	suppressed
Diazepam	Diazepam	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	18
Tramadol Hcl	Tramadol Hcl	22	15
Azithromycin	Azithromycin	21	19
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	12
Ozempic	Semaglutide	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	15
Methocarbamol	Methocarbamol	17	suppressed
Doxepin Hcl	Doxepin Hcl	16	suppressed
Fluconazole	Fluconazole	16	13
Ibuprofen	Ibuprofen	16	suppressed
Morphine Sulfate	Morphine Sulfate	16	15
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Divalproex Sodium	Divalproex Sodium	14	suppressed
Haloperidol	Haloperidol	14	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	11
Roflumilast	Roflumilast	14	suppressed
Allopurinol	Allopurinol	13	suppressed
Dexamethasone	Dexamethasone	13	13
Dutasteride	Dutasteride	13	suppressed
Linzess	Linaclotide	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Primidone	Primidone	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	12
Desloratadine	Desloratadine	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Glipizide	Glipizide	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Ranolazine Er	Ranolazine	12	suppressed
Torsemide	Torsemide	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	11	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	11	suppressed
Tradjenta	Linagliptin	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error